Quick Read – XBI surged 17% last month and 89% over the trailing year, driven entirely by pure-play biotech names with no megacap ballast. – NVIDIA dropped 12% over the same stretch, making XBI’s zero-chip-stock design a natural hedge against AI concentration risk. – XBI’s…
ve-year return of just 15% signals that biotech endures long underperformance stretches between high-momentum runs like this one. – Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over the trailing month ending July 1, 2026, a run that would look right at home in the AI trade
The twist: XBI owns exactly zero shares of NVIDIA (NASDAQ:NVDA), the chipmaker that has defined this cycle’s growth narrative. Over the same month, NVIDIA shares fell 11.84%, and the S&P 500 slipped 1.94%. A high-flying growth fund ripping higher while the AI leader cooled off is exactly the kind of rotation worth watching for retirement-focused investors.
What XBI Actually Is XBI is State Street’s SPDR-branded biotech ETF, structured to give equal-weighted exposure to the biotech industry rather than concentrating capital in a handful of megacaps. The fund carries a net expense ratio of 0.35%, a low-cost profile consistent with passive sector exposure. Because the sleeve is equal-weighted, the top 10 positions represent just 12.76% of net assets.